Our Team

Dave Boyle joined the LumaBridge team in March of 2022 with the goal of helping build and expand the business. Mr. Boyle is a longtime veteran of the biopharma industry and has held senior management positions in the Ares Serono Group, Salix Pharmaceuticals, XOMA, AVI BioPharma, and most recently, LakePharma, where he assisted with the successful sale of the business to Curia Global.

Mr. Boyle has an international background, with experience working in Europe for several years with Ernst & Young and the Ares Serono Group. Having lost 2 close colleagues to cancer, Dave’s interest is in working with a team that can make a real difference by helping to advance promising innovative therapies for the benefit of patients.

COL (ret) George E. Peoples, MD, FACS, is the founder, CSO, and executive chairman of LumaBridge (formerly Cancer Insight [CI]) and Trauma Insight (TI). He served 30 years of active duty as a surgeon and research scientist in the military and was founder and director of the Cancer Vaccine Development Program (CVDP). The CVDP has over 20 years of experience in the discovery, development, and clinical testing of cancer vaccines, including 5 that have been licensed for commercial development. In 2014, Dr. Peoples retired from the military and founded CI and TI.

Dr. Peoples serves as a professor of surgery at Uniformed Services University of the Health Sciences and professor (adjunct) of surgical oncology at MD Anderson Cancer Center (MDACC). He is the former chair of the Cancer Care Program at the San Antonio Military Medical Center and the past military director of the United States Military Cancer Institute. He is a graduate of the United States Military Academy at West Point and the Johns Hopkins School of Medicine. He completed his surgical training at Harvard’s Brigham and Women’s Hospital and a surgical oncology fellowship at MDACC. He has written extensively on the immune response to cancer, with over 300 peer-reviewed manuscripts, abstracts, and book chapters.

Lori McDermott is a clinical operations executive with nearly 25 years of industry experience, currently serving as COO of LumaBridge. In this role, she leads the workforce and business strategies in supporting oncology development programs for emerging biotech and pharmaceutical clients.  ​

Before joining LumaBridge, Ms. McDermott held the position of vice president of clinical development and regulatory affairs at Heat Biologics and Pelican Therapeutics, where she was responsible for driving forward the clinical development of 4 novel oncology assets. In the years preceding her work there, Ms. McDermott held roles across biotech, pharma, and clinical contract research organization (CRO) settings and developed expertise in managing immuno-oncology clinical programs. ​

Ms. McDermott began her career in the hospital, providing bedside care as a registered nurse before transitioning into clinical research. Ms. McDermott is PMP® certified and holds a bachelor’s degree in nursing from Neumann College as well as a master of science from Drexel University School of Medicine.

Alexander Stojadinovic, the new CMO of LumaBridge, brings extensive experience in strategic planning, program development, team building, operations, and research and development. He has served as senior medical director in oncology clinical development at GlaxoSmithKline, as medical director of healthcare management services for Amerigroup Texas, and as a consulting surgical oncologist and healthcare executive. He was a founding partner of the Institute for Hyperthermic Regional Perfusion as well as 3rd Curve Healthcare. He was regional director of Bon Secours Cancer Institute in Virginia, and as a surgical oncology consultant, he continues to see patients and operate at Bon Secours Mercy Healthcare System’s Saint Mary’s Hospital.  

Dr. Stojadinovic received his executive education in general management at the Harvard Business School. He completed a physician executive master’s of business administration (PEMBA) at the University of Tennessee, Knoxville, and a master of science in regulatory science at the University of Maryland School of Pharmacy. He is a graduate of the United States Military Academy and the Uniformed Services University of the Health Sciences in Bethesda, Maryland, where he received his medical degree. He was recognized with multiple clinical excellence awards during his general surgical residency at Walter Reed Army Medical Center. While completing his surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC), he became the first recipient of the MSKCC Award for Excellence in Clinical Research. He serves on the editorial boards of the Journal of Surgical Oncology, the Journal of Cancer, and Clinical Medicine Insights: Oncology and as the associate editor-in-chief of several other journals.

Steven White is the CFO of LumaBridge and helped found the company (as Cancer Insight) in 2014. After graduating from Trinity University, Mr. White practiced as an accountant in tax and assurance services for several years. He later went on to earn his law license and practiced as a business and contracts attorney in San Antonio, Texas. Since helping found LumaBridge, he has worked closely with teams across all areas of the company, giving him a deep appreciation for their work and the company’s mission.

During his time with LumaBridge, Mr. White has helped support both the company’s academic background and its growth by contributing to commercial development. He believes the most important thing LumaBridge does is act as a development partner to support promising therapies for patients.

Todd Lehman

Todd brings almost 20 years of experience in client services and in commercial and clinical operations to LumaBridge as the head of business development. Prior to joining LumaBridge, Todd held various leadership roles in operations and portfolio management with a focus on the biotech customer while at PPD, part of Thermo Fisher Scientific. He got his start in the industry in 2004 with Rx Development Resources, a start-up niche CRO that transformed into Sirion Therapeutics, a small biotech. Sirion in-licensed 5 ex-US assets and received 2 marketing approvals over a 3-year period.    

Todd has experience across several therapeutic areas, with focus in oncology and ophthalmology, and holds a bachelor's degree in chemical engineering and a master's in biomedical engineering from the University of South Florida. Prior to his time in clinical research, Todd spent about 10 years in retail and b2b commodity sales.